These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16806136)

  • 21. [Severe type III hyperlipoproteinemia with unusual lipoprotein phenotype in an adolescent patient].
    Ziemer A; Göring HD
    Hautarzt; 1993 Aug; 44(8):538-44. PubMed ID: 8376110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
    Wissing KM; Unger P; Ghisdal L; Broeders N; Berkenboom G; Carpentier Y; Abramowicz D
    Transplantation; 2006 Sep; 82(6):771-8. PubMed ID: 17006324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
    Asztalos BF; Le Maulf F; Dallal GE; Stein E; Jones PH; Horvath KV; McTaggart F; Schaefer EJ
    Am J Cardiol; 2007 Mar; 99(5):681-5. PubMed ID: 17317371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preparative free-solution isotachophoresis for separation of human plasma lipoproteins: apolipoprotein and lipid composition of HDL subfractions.
    Böttcher A; Schlosser J; Kronenberg F; Dieplinger H; Knipping G; Lackner KJ; Schmitz G
    J Lipid Res; 2000 Jun; 41(6):905-15. PubMed ID: 10828082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
    Burnett JR; Barrett PH; Vicini P; Miller DB; Telford DE; Kleinstiver SJ; Huff MW
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1906-14. PubMed ID: 9848883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
    Betteridge DJ; Gibson JM
    Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of atorvastatin on type 2 diabetic dyslipidemia.
    Save V; Patil N; Moulik N; Rajadhyaksha G
    J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):262-70. PubMed ID: 17220473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Separation of lipoproteins by capillary isotachophoresis combined with enzymatic derivatization of cholesterol and triglycerides.
    Zorn U; Wolf CF; Wennauer R; Bachem MG; Grünert A
    Electrophoresis; 1999 Jun; 20(7):1619-26. PubMed ID: 10424488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
    Alrasadi K; Awan Z; Alwaili K; Ruel I; Hafiane A; Krimbou L; Genest J
    Am J Cardiol; 2008 Nov; 102(10):1341-7. PubMed ID: 18993152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study.
    Zhang B; Matsunaga A; Rainwater DL; Miura S; Noda K; Nishikawa H; Uehara Y; Shirai K; Ogawa M; Saku K
    J Lipid Res; 2009 Sep; 50(9):1832-41. PubMed ID: 19056704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
    Ky B; Burke A; Tsimikas S; Wolfe ML; Tadesse MG; Szapary PO; Witztum JL; FitzGerald GA; Rader DJ
    J Am Coll Cardiol; 2008 Apr; 51(17):1653-62. PubMed ID: 18436117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atorvastatin effect on circulating and leukocyte-produced CD40 ligand concentrations in people with normal cholesterol levels: a pilot study.
    Zineh I; Welder GJ; DeBella AE; Arant CB; Wessel TR; Schofield RS
    Pharmacotherapy; 2006 Nov; 26(11):1572-7. PubMed ID: 17064201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.